Upadacitinib versus placebo or adalimumab with background methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate: a subgroup analysis of a phase III randomized controlled trial in Central and Eastern European patients

BACKGROUND: In the randomized, phase III, global SELECT-COMPARE study, upadacitinib 15 mg demonstrated efficacy at week 12 versus placebo and adalimumab with methotrexate (MTX) in patients with rheumatoid arthritis and inadequate response to MTX, which was maintained over 48 weeks. This post hoc ana...

Descripción completa

Detalles Bibliográficos
Autores principales: Pavelka, Karel, Szekanecz, Zoltán, Damjanov, Nemanja, Anić, Branimir, Tomšič, Matija, Mazurov, Vadim, Maksimovic, Marija, Nagy, Orsolya, Świerkot, Jerzy, Petranova, Tzvetanka, Veldi, Tiina, Baranauskaitė, Asta, Codreanu, Catalin, Andersone, Daina, Fleischmann, Roy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioExcel Publishing Ltd 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7574850/
https://www.ncbi.nlm.nih.gov/pubmed/33123205
http://dx.doi.org/10.7573/dic.2020-7-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7574850/
https://www.ncbi.nlm.nih.gov/pubmed/33123205
http://dx.doi.org/10.7573/dic.2020-7-5

Ejemplares similares